Phase II study evaluating the safety and efficacy of neratinib and trastuzumab biosimilar in patients with HER2 mutated advanced solid tumors: KCSG AL20-17/KM23 trial.

ABSTRACT:

SUBMITTER: Lee K 

PROVIDER: S-EPMC12328084 | biostudies-literature | 2025 Jul

REPOSITORIES: biostudies-literature